Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Cerilliant
Cipla
AstraZeneca
Johnson and Johnson
Queensland Health
McKesson
Teva
US Department of Justice

Generated: October 19, 2017

DrugPatentWatch Database Preview

KERLEDEX Drug Profile

« Back to Dashboard

Which patents cover Kerledex, and when can generic versions of Kerledex launch?

Kerledex is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in KERLEDEX is betaxolol hydrochloride; chlorthalidone. There are eleven drug master file entries for this compound. Additional details are available on the betaxolol hydrochloride; chlorthalidone profile page.

Summary for Tradename: KERLEDEX

US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list40
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:KERLEDEX at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
KERLEDEX
betaxolol hydrochloride; chlorthalidone
TABLET;ORAL019807-001Oct 30, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
KERLEDEX
betaxolol hydrochloride; chlorthalidone
TABLET;ORAL019807-002Oct 30, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: KERLEDEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
KERLEDEX
betaxolol hydrochloride; chlorthalidone
TABLET;ORAL019807-001Oct 30, 1992► Subscribe► Subscribe
Sanofi Aventis Us
KERLEDEX
betaxolol hydrochloride; chlorthalidone
TABLET;ORAL019807-002Oct 30, 1992► Subscribe► Subscribe
Sanofi Aventis Us
KERLEDEX
betaxolol hydrochloride; chlorthalidone
TABLET;ORAL019807-002Oct 30, 1992► Subscribe► Subscribe
Sanofi Aventis Us
KERLEDEX
betaxolol hydrochloride; chlorthalidone
TABLET;ORAL019807-001Oct 30, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Citi
Julphar
Express Scripts
Merck
UBS
Novartis
Cantor Fitzgerald
Fuji
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot